THE COMPLETE GUIDE TO

INDENTIFYING

RECORD-BREAKING

TRADES

FEATURING THE 10 KEYS FOR MASSIVE SUCCESS

J. DARYL THOMPSON

MY NAME IS
DARYL THOMPSON

My name is Daryl Thompson and for the last 18 months, I’ve been studying the medical stock world like an obsessed man. I’ve read more charts, analyzed more CEO’s, and broken down more record-breaking trades in the medical field then I ever would have imagined.
2
IN MY RESEARCH, SEVERAL KEYS CONTINUED TO COME OUT OVER AND OVER AGAIN AMONG THOSE RECORD-BREAKERS

Every time one of keys came up, I sat back in my chair and realized that there HAD to be something that kept making these medical specific stocks go off the charts. So in my own tedious way, I began to watch...track...and trade these winners.

During that time I was diagnosed with cancer (but now, I’m currently in 100% remission!).

However during that time I, like a LOT of patients, began to research the medical marijuana world.

My research led me into some crazy places...however as time has gone on, and it’s become more MEDICAL...I came across the reality that some of these publicly traded stocks COULD BE 10X medical stocks!

In fact, as my research went on, I began to see some PATTERNS repeating themselves in some of these marijuana stocks. Actually there’s one in particular that has ALL the key points, but first let me take you where my research led me so YOU have the chance to make big money trading.

WITHOUT FURTHER ADIEU: BREAKING THE CODE TO IDENTIFYING 10X RECORD BREAKING STOCKS.

Here are the 10 Key-Factors you’ll need to understand for EVERY biotech investment you’ll ever make.

3

01

MARKETING POTENTIAL

For a soft lead-in, think for a moment about what you’ve been watching in the news or reading about online. Most likely, this is where the industry is heading and putting their time and money towards finding a treatment/cure for society’s most prevalent medical concerns.
THIS SHOWS MARKET POTENTIAL

The first question you should ask yourself is…Is there an opportunity in the market? America is getting older and STILL not as healthy as many developed countries around the world. Living in an aging society, where we aren’t necessarily living healthier lives, but managing to live decades longer than just a generation ago, necessitates a continuing pipeline of novel drugs available to consumers. Thankfully, cutting-edge pharmaceuticals and treatments have been entering the market year-after-year to sustain our way of life.

By 2040, 40 million people will be added to Medicare and the US Healthcare system is already transitioning.

BY 2060, THE NUMBER WILL DOUBLE.

Just last week, two hospitals opened in my metropolitan area, catering specifically to seniors. Just as Children’s Mercy has become the go-to choice for newborn babies and children with life-threatening illness and disease, now there are hospitals accommodating only to the senior population.

5
THIS IS PROVIDING INVESTORS WITH MORE OPPORTUNITIES THAN EVER BEFORE IN A CONTINUALLY GROWING MARKET.

This tidal wave is built on advances in medicine, helping individuals live longer than ever before. What’s more, Baby Boomers, who have been able to accumulate more money than any generation in history are spending it on healthcare. And, not only is this demographic growing, but their willingness to take a variety of market-ready and developing drugs is too. If they can get them, they’re buying them -- AND more than ever before.

Source: Centers for Disease Control and Prevention

6

Generally, it’s pretty obvious that big pharma and biotech are continuing to produce some of the fastest growing companies in the world. But, how do I know which one is developing a drug or treatment that is going to be the next 10X groundbreaking stock? Well, like most things, taking a look at the past will help us discover what to look out for heading into the future.

One of the things I look out for is headlining news. That’s why most investors are constantly surrounded by various forms of media, press releases and banners of changing ticker prices. Considering this, it is important to keep things relatively simple at the beginning of your search. When scanning the industry of big pharma, look out for a search for a cure or a better treatment option in a big market. This is a key indicator that there is a significant opportunity waiting to be unearthed.

This may sound overly simplistic, but too often investors search for miniscule biotech’s with treatments or drugs for nearly unheard-of diseases. There’s little wonder why they’re left holding the bag when their company couldn’t get through their clinical trials or generate enough revenue to give investors any return even after FDA approval.

7

Are patients and doctors satisfied with the options available for treatments for a specific illness or disease? Or, are they searching for something better? Think diabetes, heart diseases, neurological diseases or cancers, where much of the population is affected. Think about AIDS in the 90s or the current opioid epidemic.

If you ever saw the movie “Dallas Buyers Club” with Matthew McConaughey, you might remember the drug AZT depicted in the movie. In essence, in a rush to discover a treatment during the AIDS epidemic in the 90’s, a once looked-over drug that had failed to effectively treat cancer was used to treat AIDS -- and with positive results. Although discovering the proper dosage took some years to perfect (as characters in the movie can be seen having significant side effects) and the compound changed over time, its usage caused the AIDS fatality rate to decrease by more than 80%. The drug became known as Combivir and to date, it is the top-selling HIV antiretroviral drug in history, making billions of dollars for investors and saving countless lives around the world. This only occurred because of a man named Dr. Samuel Broder believed in a drug that had been passed over for 20 years, and was willing to pick it up off the shelf, adapting it for new applications.

Can you imagine if a biotech developed a new pain killer that was less, or nearly non-addictive, compared to market available drugs like codeine, fentanyl or hydrocodone? So- ciety, pharma, and even the government is going in a fren- zy right now to find a cure to the opioid epidemic that is sweeping the country.

8

As deaths have increased due to increased opioid prescriptions and addiction, the government has begun to highly regulate the market. But, this won’t decrease the overall sales of painkiller or decrease prescriptions. What it will do is dramatically change the playing field. This summer, Purdue Pharma, the producer of OxyContin, the biggest selling opioid on the market, laid off most of its sales force and is in steadily downsizing operations. This leaves a huge void to be filled by a company that can develop a safer but effective treatment.

This has immediately created an opportunity for R&D teams across the world. The first company to find the best solution for the market will assure themselves of some substantial immediate AND long-term gains. Doctors are already looking for alternative prescription options for patients due to increased scrutiny and oversight. With pain relief being the biggest, broadest and currently most challenging sector in the pharmaceutical industry, science will soon discover new treatment options, offering the market what it needs. But, believe it or not, it won’t be opioids.

9

02

EXPERIENCED MANAGEMENT

Most would assume that a pharmaceutical company is by default, being managed by qualified people. While this may be true, it is important to understand what types of qualifications are held by the founders and/or board members. A room full of PhD’s, Chemists and Pharmaceutical Scientists don’t necessarily have what it takes to sustain a viable company or get a drug to market. This is something to keep in mind when considering whether to invest in a startup.
11